Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...
Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to ...
Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to ...
Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...
The analysis included 66 visits: 23 and 43 visits were assigned emergency severity index 2 and 3. HealthDay News — A majority of patients with sickle cell disease (SCD) with vaso-occlusive crisis (VOC ...
June 19 is marked as World Sickle Cell Awareness Day, granting the opportunity to reflect on the current state of treatment, access, equity, and more that impacts patients living with sickle cell ...
Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...
2025 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Data detailed on Managed Care have been presented. According to news reporting out of Washington, District of ...
Two Pee Dee siblings are officially cured of sickle cell disease after more than a decade of living with the genetic blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results